Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

1st timeframe trend

Score

0.15

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 54 8.1 0.43% 0.74% 13.9% -4.4% 183.8%
SHORT 54 7.2 0.35% 0.53% 5.9% -4.8% -60.3%

Summary

Technical Analysis


The Tricklar short term trend indicator (T1) highlights the high points and low points associated with the individual bars. As such, successive rallies penetrating preceding high points whilst cancelling preceding lower troughs offer a BULLISH indication in the second time frame. Conversely, failure of rallies to penetrate previous Lower peaks whilst maintaining prices below the previous lower troughs indicates BEARISH trends in the second timeframe.

Calculation: Tricklar short trend (T1):
1) [BULLISH] An uptrend is a succession of higher highs and higher lows;
2) [BEARISH] A downtrend is a succession of lower highs and lower lows;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

1st timeframe trend

Download
Company Close Change(%) Volume Value Signal
INO Inovio Pharma 4.36 9.3 34,675,337 -1 BEARISH
KPTI Karyopharm Therapeutics 15.38 7 1,860,063 -1 BEARISH
FOSL Fossil Group 4.28 2.6 1,864,683 -1 BEARISH
NH Nanthealth 1.8 1.7 455,155 -1 BEARISH
AMTD Td Ameritrade 43.75 1 10,178,180 -1 BEARISH
FANH Fanhua 20.69 0.2 134,459 -1 BEARISH
PRMW Primo Water 14.91 0 707,726 -1 BEARISH
AXGN Axogen 12.98 -0.1 418,801 -1 BEARISH
SRCL Stericycle Inc 61.46 -0.4 868,471 -1 BEARISH
IRTC Irhythm Technologies 80.4 -0.8 452,782 -1 BEARISH